nChroma Bio
PrivateLast Round
Series I
Dec 11, 2024
Total Funding Raised
$435M
Momentum
Top 50%
of companies Caplight tracks
Company Overview
nChroma Bio is a biotechnology company that develops in vivo targeted genetic medicines to treat a wide array of diseases.
Sector
Healthcare & Life Sciences
Verticals
Biotechnology, Drug Discovery, Precision Medicine, Clinical Trials
Business Model
B2B
Customer Profile
Revenue Share, Government Contracts
AI Layer
Non-AI
Keywords
Historical Pricing
Historical view of private secondary pricing and transaction trends.
nChroma Bio Comparables
Compare nChroma Bio with similar companies based on industry and business-model similarity.
| Company | Similarity | Market Cap |
|---|---|---|
| Tune Therapeutics | 93% | |
| Epicrispr Biotechnologies | 82% | |
| Omega Therapeutics | 80% | |
nChroma Bio Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| Series I | Dec 11, 2024 | ||||
| Series B | Mar 1, 2023 | ||||
| Series A | Nov 17, 2021 |
Key People
Founding team and executive leadership
nChroma Bio Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| Newpath Partners | Seed, Series B, Series A, Series I |
| Janus Henderson Group | Series I, Series B, Series A |
| Omega Funds | Series I, Series B, Series A |
| GV | Series I, Seed, Series B |
| DCVC Bio | Series I, Series B |
| ARCH Venture Partners | Series I |
| F-Prime Capital | Series I, Seed |
Market signals
Structured signals derived from secondary market and firmographic data.
- Jun 21, 2026
Monthly visitors increased 65% MoM.
- Jan 1, 2026
CRMA-1001 is an epigenetic silencer for chronic hepatitis B.
nChroma Bio Filings
SEC and related filings with document metadata.
| Typed | Date | Amount Offered | Amount Sold | Filling | Pages | Download |
|---|---|---|---|---|---|---|
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Frequently Asked Questions
Common questions about nChroma Bio's valuation, stock price, and market status.